Yusuke Asai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yusuke Asai has a total of 231 co-authors. Here are the top co-authors by number of shared publications:
Norio Ohmagari
27 shared publications- Shinya Tsuzuki
AMR Clinical Reference Center, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan
20 shared publications Nobuaki Matsunaga
AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan
14 shared publicationsNoriko Iwamoto
Disease Control and Prevention Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, 162-8655, Tokyo, Japan
9 shared publications- Kayoko Hayakawa
Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security
7 shared publications Kayoko Hayakawa
6 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Elsevier in Journal of Global Antimicrobial Resistance
Clinical Outcomes of Carbapenem-Resistant versus Carbapenem-Susceptible Pseudomonas aeruginosa Infections in Japan: A Multicenter Matched Case-Control Study by the Multi-Drug Resistant Organisms Clinical Research Network (MDRnet)
- 4 November 2026
- Published by Elsevier in Journal of Global Antimicrobial Resistance
Open AccessClinical Outcomes of Carbapenem-Resistant versus Carbapenem-Susceptible Pseudomonas aeruginosa Infections in Japan: A Multicenter Matched Case-Control Study by the Multi-Drug Resistant Organisms Clinical Research Network (MDRnet)
- 10 August 2026
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (11) , 107954
Development of the susceptibility–spectrum discrepancy index (S2DI): A novel metric for antimicrobial stewardship in hospitalised patients
- 10 August 2026
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (11) , 107954
Development of the susceptibility–spectrum discrepancy index (S2DI): A novel metric for antimicrobial stewardship in hospitalised patients
- Open Access
- 2 June 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (6) , e0100726
Difficult-to-treat resistance (DTR), treatment, and outcomes of carbapenem-resistant Enterobacterales infections in the setting of IMP-type carbapenemase predominance in Japan
Carbapenem-resistant Enterobacterales (CRE) pose a global threat due to limited treatment options and high mortality. Difficult-to-treat resistance (DTR), defined as non-susceptibility to all conventional β-lactams and fluoroquinolones, has primarily been applied to Pseudomonas aeruginosa . However, its relevance for Enterobacterales remains unclear, particularly in regions with a distinct carbapenemase landscape, such as Japan where IMP-type metallo-β-lactamases predominate. We analyzed the MultiDrug-Resistant organisms clinical research network (MDRnet) cohort, a multicenter prospective study conducted at 13 Japanese hospitals between April 2019 and March 2024. This analysis included patients with clinically indicated cultures yielding CRE. Clinical characteristics and outcomes assessed using the desirability of outcome ranking (DOOR) framework and genomic epidemiology characterized by whole-genome sequencing were compared between DTR and non-DTR groups. Among 196 CRE cases, 64 (32.7%) represented infections, including 12 DTR cases (18.8%). Carbapenemase genes were detected in 34/64 infections (53.1%), with similar prevalence in the DTR and non-DTR groups (50.0% vs 53.8%). bla IMP-1 was the most frequently identified carbapenemase gene ( n = 28). The overall 30-day mortality rate was 21.9%, with 16.7% (95% confidence interval [CI], 2.1%–48.4%) in the DTR group and 23.1% (95% CI, 12.5%–36.8%) in the non-DTR group. DOOR outcomes were similar between groups. Appropriate empiric and definitive therapy was less frequently administered in the DTR group. In this cohort, where IMP-type carbapenemases and non-DTR CRE are prevalent, DTR classification did not appear to correlate with 30-day mortality or DOOR outcomes. These findings underscore the importance of regional molecular epidemiology when interpreting clinical outcomes of CRE infections. IMPORTANCE: Difficult-to-treat resistance (DTR) is increasingly used to assess the clinical impact of antimicrobial resistance, but its significance in carbapenem-resistant Enterobacterales (CRE) may vary across molecular epidemiologic settings. In this prospective multicenter study from Japan, where IMP-type carbapenemases predominated, most CRE infections were classified as non-DTR. Whole-genome sequencing also revealed a distinct local clonal structure. DTR was not associated with 30-day mortality or desirability of outcome ranking despite lower rates of appropriate empiric and definitive therapy. Our study highlights the importance of interpreting DTR in CRE within the context of regional molecular epidemiology and supports the need for continued regional multicenter studies to evaluate its clinical utility.
- 2 June 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (6) , e0100726
Open AccessDifficult-to-treat resistance (DTR), treatment, and outcomes of carbapenem-resistant Enterobacterales infections in the setting of IMP-type carbapenemase predominance in Japan
Carbapenem-resistant Enterobacterales (CRE) pose a global threat due to limited treatment options and high mortality. Difficult-to-treat resistance (DTR), defined as non-susceptibility to all conventional β-lactams and fluoroquinolones, has primarily been applied to Pseudomonas aeruginosa . However, its relevance for Enterobacterales remains unclear, particularly in regions with a distinct carbapenemase landscape, such as Japan where IMP-type metallo-β-lactamases predominate. We analyzed the MultiDrug-Resistant organisms clinical research network (MDRnet) cohort, a multicenter prospective study conducted at 13 Japanese hospitals between April 2019 and March 2024. This analysis included patients with clinically indicated cultures yielding CRE. Clinical characteristics and outcomes assessed using the desirability of outcome ranking (DOOR) framework and genomic epidemiology characterized by whole-genome sequencing were compared between DTR and non-DTR groups. Among 196 CRE cases, 64 (32.7%) represented infections, including 12 DTR cases (18.8%). Carbapenemase genes were detected in 34/64 infections (53.1%), with similar prevalence in the DTR and non-DTR groups (50.0% vs 53.8%). bla IMP-1 was the most frequently identified carbapenemase gene ( n = 28). The overall 30-day mortality rate was 21.9%, with 16.7% (95% confidence interval [CI], 2.1%–48.4%) in the DTR group and 23.1% (95% CI, 12.5%–36.8%) in the non-DTR group. DOOR outcomes were similar between groups. Appropriate empiric and definitive therapy was less frequently administered in the DTR group. In this cohort, where IMP-type carbapenemases and non-DTR CRE are prevalent, DTR classification did not appear to correlate with 30-day mortality or DOOR outcomes. These findings underscore the importance of regional molecular epidemiology when interpreting clinical outcomes of CRE infections. IMPORTANCE: Difficult-to-treat resistance (DTR) is increasingly used to assess the clinical impact of antimicrobial resistance, but its significance in carbapenem-resistant Enterobacterales (CRE) may vary across molecular epidemiologic settings. In this prospective multicenter study from Japan, where IMP-type carbapenemases predominated, most CRE infections were classified as non-DTR. Whole-genome sequencing also revealed a distinct local clonal structure. DTR was not associated with 30-day mortality or desirability of outcome ranking despite lower rates of appropriate empiric and definitive therapy. Our study highlights the importance of interpreting DTR in CRE within the context of regional molecular epidemiology and supports the need for continued regional multicenter studies to evaluate its clinical utility.
- Open Access
- 7 March 2026
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 71, 102966
Development of machine-learning models to diagnose influenza among international travellers based on symptoms and epidemiological information
- 7 March 2026
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 71, 102966
Open AccessDevelopment of machine-learning models to diagnose influenza among international travellers based on symptoms and epidemiological information
- Open Access
- 17 November 2025
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (1) , 107667
Impact of antimicrobial resistance measures and the emergence of COVID-19 on antimicrobial use throughout the Japanese population: A retrospective cohort study using a national claims database
- 17 November 2025
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 67 (1) , 107667
Open AccessImpact of antimicrobial resistance measures and the emergence of COVID-19 on antimicrobial use throughout the Japanese population: A retrospective cohort study using a national claims database
- 8 November 2025
- Published by Elsevier in Journal of Theoretical Biology
- Vol. 618, 112315
Evaluating the impact of NPC1 single nucleotide polymorphisms on entry efficiency of filoviruses in vitro: Agent-based model approach
- 8 November 2025
- Published by Elsevier in Journal of Theoretical Biology
- Vol. 618, 112315
Evaluating the impact of NPC1 single nucleotide polymorphisms on entry efficiency of filoviruses in vitro: Agent-based model approach
- Open Access
- 14 July 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e156
Factors associated with using penicillins as the first-choice antimicrobial among dentists in Japan: a national cross-sectional study
Objective: This study aimed to identify the factors associated with the use of penicillins as the first-choice antimicrobial in Japan’s dental clinics. Design: Cross-sectional questionnaire-based survey. Setting: Dental clinics throughout Japan. Participants: Dentists at the participating clinics. Methods: Questionnaires were sent to 1,700 dental care facilities in July 2020, and responses were collected until September 2020. The survey gathered data on clinic characteristics, provision of on-site antimicrobial dispensing, choice of antimicrobials, and knowledge regarding antimicrobial resistance (AMR) and infective endocarditis (IE). Descriptive epidemiology and logistic regression analyses were performed to identify the factors associated with on-site dispensing of penicillins and their use as the first-choice antimicrobial. Results: Responses were obtained from 342 (response rate: 20.1 %) dentists from dental clinics. While 93.9% of respondents were aware of the term “AMR,” only 20.8% were familiar with Japan’s National Action Plan on AMR. AMR countermeasures were implemented in 79.4% of clinics, but 58.4% of respondents lacked awareness of IE guidelines. In the multivariable logistic regression analyses, “adherence to IE guidelines” (odds ratio: 2.56, P = .001) and “clinic stocks ≥2 antimicrobials” (5.02, P = .002) were positively associated with on-site dispensing of penicillins. In contrast, “clinic with ≥2 full-time dentists” (odds ratio: .45, P = .033) was negatively associated with the use of penicillins as the first-choice antimicrobial. Conclusions: There was a low awareness of the National Action Plan and IE guidelines among dentists. Enhancing educational activities and fostering environments that facilitate collaborative decision-making regarding antimicrobial use may help to improve antimicrobial stewardship in Japan’s dental clinics.
- 14 July 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e156
Open AccessFactors associated with using penicillins as the first-choice antimicrobial among dentists in Japan: a national cross-sectional study
Objective: This study aimed to identify the factors associated with the use of penicillins as the first-choice antimicrobial in Japan’s dental clinics. Design: Cross-sectional questionnaire-based survey. Setting: Dental clinics throughout Japan. Participants: Dentists at the participating clinics. Methods: Questionnaires were sent to 1,700 dental care facilities in July 2020, and responses were collected until September 2020. The survey gathered data on clinic characteristics, provision of on-site antimicrobial dispensing, choice of antimicrobials, and knowledge regarding antimicrobial resistance (AMR) and infective endocarditis (IE). Descriptive epidemiology and logistic regression analyses were performed to identify the factors associated with on-site dispensing of penicillins and their use as the first-choice antimicrobial. Results: Responses were obtained from 342 (response rate: 20.1 %) dentists from dental clinics. While 93.9% of respondents were aware of the term “AMR,” only 20.8% were familiar with Japan’s National Action Plan on AMR. AMR countermeasures were implemented in 79.4% of clinics, but 58.4% of respondents lacked awareness of IE guidelines. In the multivariable logistic regression analyses, “adherence to IE guidelines” (odds ratio: 2.56, P = .001) and “clinic stocks ≥2 antimicrobials” (5.02, P = .002) were positively associated with on-site dispensing of penicillins. In contrast, “clinic with ≥2 full-time dentists” (odds ratio: .45, P = .033) was negatively associated with the use of penicillins as the first-choice antimicrobial. Conclusions: There was a low awareness of the National Action Plan and IE guidelines among dentists. Enhancing educational activities and fostering environments that facilitate collaborative decision-making regarding antimicrobial use may help to improve antimicrobial stewardship in Japan’s dental clinics.
- Open Access
- 21 January 2025
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (4) , 102631
Duration of infectious virus shedding of SARS-CoV-2 Omicron variant among immunocompromised patients
- 21 January 2025
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (4) , 102631
Open AccessDuration of infectious virus shedding of SARS-CoV-2 Omicron variant among immunocompromised patients
- 11 September 2024
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (2) , 102520
Comparison of clinical characteristics and severity of COVID-19 with or without viral co-infection in hospitalized children
- 11 September 2024
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (2) , 102520
Comparison of clinical characteristics and severity of COVID-19 with or without viral co-infection in hospitalized children
- Open Access
- 12 June 2024
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 17 (8) , 102474
Evaluation of antimicrobial selective pressure using the multicenter semiautomatic surveillance system Japan surveillance for infection prevention and healthcare epidemiology
- 12 June 2024
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 17 (8) , 102474
Open AccessEvaluation of antimicrobial selective pressure using the multicenter semiautomatic surveillance system Japan surveillance for infection prevention and healthcare epidemiology